A pioneering study, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.
Semaglutide improves outcomes for obese patients with common skin condition, new study shows retrieved 25 September 2024 from https://medicalxpress.com/news/2024-09-semaglutide-outcomes-obese-patients-common.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Sep 19, 2024Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study warns of high Medicare costs for semaglutide even with restrictive CVD definitionIf Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion
Read more »
Study finds weight loss drug semaglutide reduced COVID-19 related deaths during the pandemicPatients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, finds.
Read more »
Study reassures patients about semaglutide safetyTaking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal...
Read more »
How Does Semaglutide Work to Lose Weight?Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for obesity and type 2 diabetes management.
Read more »
Semaglutide shows promise in treating chronic skin condition in obese patientsA pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.
Read more »
Analysis finds no increased risk of mental health issues among those using semaglutide for weight lossTaking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published in JAMA Internal Medicine.
Read more »